Mirae Asset Global Investments Co. Ltd. Grows Stock Holdings in Pfizer Inc. (NYSE:PFE)

Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Pfizer Inc. (NYSE:PFE) by 35.3% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,907,682 shares of the biopharmaceutical company’s stock after acquiring an additional 1,019,400 shares during the period. Mirae Asset Global Investments Co. Ltd. owned about 0.07% of Pfizer worth $104,000,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the company. Czech National Bank increased its holdings in shares of Pfizer by 6.9% in the 3rd quarter. Czech National Bank now owns 1,154,366 shares of the biopharmaceutical company’s stock valued at $33,407,000 after acquiring an additional 74,737 shares during the period. GAMMA Investing LLC boosted its position in Pfizer by 48.9% during the third quarter. GAMMA Investing LLC now owns 39,904 shares of the biopharmaceutical company’s stock valued at $1,155,000 after purchasing an additional 13,097 shares in the last quarter. Diversified Trust Co grew its stake in Pfizer by 33.8% in the third quarter. Diversified Trust Co now owns 113,505 shares of the biopharmaceutical company’s stock valued at $3,285,000 after purchasing an additional 28,658 shares during the last quarter. Ignite Planners LLC lifted its position in shares of Pfizer by 1.5% during the third quarter. Ignite Planners LLC now owns 34,144 shares of the biopharmaceutical company’s stock valued at $988,000 after buying an additional 518 shares during the last quarter. Finally, Chapin Davis Inc. boosted its holdings in shares of Pfizer by 2.8% in the 3rd quarter. Chapin Davis Inc. now owns 59,981 shares of the biopharmaceutical company’s stock valued at $1,736,000 after buying an additional 1,627 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of PFE stock opened at $25.88 on Wednesday. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock has a market cap of $146.64 billion, a PE ratio of 34.97, a price-to-earnings-growth ratio of 0.66 and a beta of 0.64. The business has a 50-day simple moving average of $26.27 and a 200-day simple moving average of $27.82.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. The business had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.10 EPS. On average, equities analysts expect that Pfizer Inc. will post 2.96 EPS for the current year.

Pfizer Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.65%. This is an increase from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio is 232.44%.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Wednesday, October 23rd. Guggenheim lowered their price objective on Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. Bank of America reaffirmed a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. Truist Financial dropped their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. Finally, Wolfe Research began coverage on shares of Pfizer in a research report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price objective for the company. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.